Diet Drug Use Associated With Increased Prevalence of Heart Valve Abnormalities

April 05, 2000

New York (MedscapeWire) Apr 5 — Users of the diet drugs dexfenfluramine and phentermine/fenfluramine had more than double the risk of having developed heart valve abnormalities, according to an article appearing in the April 5 issue of The Journal of the American Medical Association. However, the researchers did not find an increased prevalence of serious cardiovascular or cardiac outcomes such as heart attack, congestive heart failure, or ventricular arrhythmia.

Julius M. Gardin, MD, from the University of California, Irvine, and colleagues evaluated the cardiovascular status and the prevalence of valvular abnormalities in 1473 patients from 25 US clinical centers who were treated for obesity with the anorexigens dexfenfluramine or phentermine/fenfluramine. The authors evaluated the prevalence of valvular abnormalities and clinical signs and symptoms in large cohorts of dexfenfluramine- and phentermine/fenfluramine-treated patients compared with an untreated control group.

According to background information in the article, in 1997 reports of valvular abnormalities resulted in the voluntary withdrawal of dexfenfluramine and fenfluramine from the market.

"Prevalence rates and relative risk (RR) of aortic regurgitation were significantly increased in anorexigen-treated patients and were 8.9% in the dexfenfluramine group (RR 2.18), 13.7% in the phentermine/fenfluramine group (RR 3.34) and 4.1% in the untreated group," write the authors.

Moderate or severe aortic regurgitation was observed infrequently. The prevalence of mitral regurgitation was approximately the same between the treated and untreated groups. There was no statistical difference in the prevalence of serious cardiac events, including heart attack, congestive heart failure or ventricular arrhythmia, between the treated and untreated groups.

In an accompanying editorial, Hershel Jick, MD, from the Boston University School of Medicine, Lexington, Mass, considers the study by Gardin and colleagues in the context of other researchers' dexfenfluramine and phentermine/fenfluramine study results. Dr. Jick cautions that the JAMA study may underestimate the actual prevalence of heart valve abnormalities related to the use of dexfenfluramine and phentermine/fenfluramine.

"Several factors apparent from the body of evidence linking fenfluramines and valve disorders appear to favor a casual connection," writes Dr. Jick. "The majority of echocardiographic studies comparing asymptomatic fenfluramine recipients with comparable nonrecipients show a substantially increased prevalence of valve disorders in the fenfluramine-treated patients. The most common abnormality is [aortic regurgitation], which is most often minor and benign (ie, associated with no cardiac symptoms), and clinically important valvular disease attributable to fenfluramines appears to be uncommon."

JAMA. 2000;283:1703-1709,1738-1740


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: